We came across a bullish thesis on Novo Nordisk A/S on Value investing subreddit by Max-lindberg. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S's share was trading at $49.35 as of November 28th. NVO’s trailing and forward P/E were 13.62 and 12.53 respectively according to Yahoo Finance.
Novo Nordisk (NVO), the Danish pharmaceutical leader behind Ozempic and Wegovy, has undergone a dramatic financial transformation driven by surging demand for its GLP-1 diabetes and obesity treatments. Over the past five years, revenue has more than doubled to...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.